The FDA has approved AstraZeneca’s danicopan (Voydeya) as add-on therapy to C5-targeted antibodies for extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH).

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

Dr Haumschild continues leading a discussion surrounding management of PNH, emphasizing the impact of complement inhibitors. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights ...

The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and ...

Medically reviewed by Matthew Wosnitzer, MD Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also ...

A new study may offer a strategy that mitigates negative side effects associated with intravenous injection of nanoparticles commonly used in medicine. The study was published today in Nature ...

The Medical University of South Carolina research team who conducted the study published in Cells included (front to back) Dr. Eliza McElwee, Dr. Stephen Tomlinson and Devin Hatchell. A research team ...